All Releases
 |
Pharmacyclics Increases Amount of Previously Announced Registered Direct Offering
Jun 17, 2010
|
9.9 KB |
|
| |
SUNNYVALE, Calif., June 17, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has increased the number of shares to be sold in the registered direct offering previously announced on June 15, 2010 by approximately 1.9 million shares, for a total offering of approximately 8 million shares. The inc...
|
|
Pharmacyclics Announces Results of Registered Direct Offering
Jun 16, 2010
|
9.5 KB |
|
| |
SUNNYVALE, Calif., June 16, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into stock purchase agreements with various institutional investors for the sale of approximately 6,150,000 shares of its common stock in a registered direct offering at $6.51 per share, the closing price o...
|
|
Pharmacyclics Announces Presentation of Results From Phase I Trial of Its First-in-Human Btk Inhibitor: PCI-32765
Jun 5, 2010
|
14.7 KB |
|
| |
CHICAGO and SUNNYVALE, Calif., June 5, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lympho...
|
|
Pharmacyclics to Present at Upcoming Investor Conferences in June
Jun 4, 2010
|
7.8 KB |
|
| |
SUNNYVALE, Calif., June 4, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced presentations at several investor conferences in June.
The confer...
|
|
Pharmacyclics Announces Oral Presentation and Material Clinical Update at the 2010 Annual Meeting of the American Society of Clinical Oncology
May 20, 2010
|
10.1 KB |
|
| |
SUNNYVALE, Calif., May 20, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the abstract it submitted for the Annual Meeting of the American Society of Clinical Oncology (ASCO), June 4-8, 2010 in Chicago, IL was released by ASCO today. The abstract was selected for an oral presentation. In the ab...
|
|
Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
May 6, 2010
|
7.4 KB |
|
| |
SUNNYVALE, Calif., May 6, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced presentations at two investor conferences in the coming week. Davi...
|
|
Pharmacyclics Reports Third Quarter Fiscal 2010 Financial Results
May 5, 2010
|
21.0 KB |
|
| |
SUNNYVALE, Calif., May 5, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its third quarter ended March 31, 2010.
Total revenues recognized under GAAP in our most recent quarter was $2.1 million. Upon the signing of a drug supply agreement with Les Laboratories ("Servier") in the...
|
|
Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Apr 15, 2010
|
11.8 KB |
|
| |
SUNNYVALE, Calif., April 15, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research (AACR) 2010 Annual Meeting being held April 17-21 in Washington, DC.
The oral presentation describes efficacy of the c...
|
|
Pharmacyclics to Present at the ROTH Capital 22nd Annual OC Growth Conference
Mar 12, 2010
|
8.6 KB |
|
| |
SUNNYVALE, Calif., March 12, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Joseph Buggy PhD, Vice President of Research, will be prese...
|
|
Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Feb 26, 2010
|
8.4 KB |
|
| |
SUNNYVALE, Calif., Feb 26, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, announced that the Company will be participating at the RBC Capital Markets Healt...
|
|
Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
Feb 11, 2010
|
29.6 KB |
|
| |
SUNNYVALE, Calif., Feb 11, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its second fiscal quarter ended December 31, 2009.
Upon the completion of a drug supply agreement with Servier in the quarter ended December 31, 2009, the company began recognizing revenue under GAAP from...
|
|
Pharmacyclics Announces Date of Second Quarter Fiscal 2010 Financial Results and Conference Call
Feb 8, 2010
|
9.5 KB |
|
| |
SUNNYVALE, Calif., Feb 08, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will report financial results for the second fiscal quart...
|
|
Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
Dec 7, 2009
|
14.0 KB |
|
| |
NEW ORLEANS and SUNNYVALE, Calif., Dec 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced interim data from a Phase I study of their novel orally administered Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) or ch...
|
|
Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
Dec 6, 2009
|
13.5 KB |
|
| |
NEW ORLEANS and SUNNYVALE, Calif., Dec 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced interim results from a Phase I/II study showing safety and clinical activity in patients with relapsed / recurrent non-Hodgkin's Lymphoma (NHL) treated with its HDAC inhibitor PCI-24781 as a single age...
|
|
Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
Dec 3, 2009
|
10.5 KB |
|
| |
SUNNYVALE, Calif., Dec 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will host a webcast and conference call on, Tues...
|
|
Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Nov 12, 2009
|
12.2 KB |
|
| |
SUNNYVALE, Calif., Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.
A material clinical u...
|
|
Pharmacyclics to Present at Merriman Curhan Ford's Investor Summit 2009
Nov 9, 2009
|
9.1 KB |
|
| |
SUNNYVALE, Calif., Nov 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Dr. David Loury, Vice President, Preclinical Develo...
|
|
Pharmacyclics Reports First Quarter Fiscal 2010 Financial Results
Oct 29, 2009
|
13.1 KB |
|
| |
SUNNYVALE, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its first fiscal quarter ended September 30, 2009. The net loss for the first quarter of fiscal 2010 was $4.8 million, or $0.12 per share, compared to a net loss of $6.5 million, or $0.25 per shar...
|
|
Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results
Sep 17, 2009
|
26.6 KB |
|
| |
SUNNYVALE, Calif., , Sept 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net l...
|
|
Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
Sep 14, 2009
|
8.3 KB |
|
| |
SUNNYVALE, Calif., Sept 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will report financial results for the fourth qu...
|
|
|
